PMID- 35211402
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220226
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Case Report: Pathological Complete Response in a Lung Metastasis of Phyllodes 
      Tumor Patient Following Treatment Containing Peptide Neoantigen Nano-Vaccine.
PG  - 800484
LID - 10.3389/fonc.2022.800484 [doi]
LID - 800484
AB  - Some of the mutant peptides produced by gene mutation transcription and 
      translation have the ability to induce specific T cells, which are called new 
      antigens. Neoantigen-based peptide, DNA, RNA, and dendritic cell vaccines have 
      been used in the clinic. In this paper, we describe a lung metastasis of a 
      phyllodes tumor patient demonstrating pathological complete response following 
      treatment containing personalized multi-epitope peptide neoantigen nano-vaccine. 
      Based on whole-exome sequencing (WES), RNA sequencing, and new antigen 
      prediction, several mutated peptide fragments were predicted to bind to the 
      patient's human leukocyte antigen (HLA) allotypes, including ten peptides with 
      high predicted binding affinity for six genes. The pulmonary metastases remained 
      stable after the four cycles of anti-PD1 and anlotinib. After the addition of the 
      multi-epitope peptide neoantigen nano-vaccine, the tumor began to collapse and 
      contracture developed, accompanied by a decrease of tumor markers to normal, and 
      complete pathological remission was achieved. With the use of the vaccination, 
      recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) was 
      used every time, and low-dose cyclophosphamide was injected every 3 weeks to 
      improve efficacy. Peripheral blood immune monitoring demonstrated immune 
      reactivity against a series of peptides, with the most robust post-vaccine T-cell 
      response detected against the HLA-DRB1*0901-restricted SLC44A5 V54F peptide.
CI  - Copyright (c) 2022 Sha, Liu, Xie, Shao, Yu, Cen, Li, Liu, Qian, Wei and Liu.
FAU - Sha, Huizi
AU  - Sha H
AD  - The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated 
      Hospital of Nanjing University Medical School, Nanjing, China.
FAU - Liu, Qin
AU  - Liu Q
AD  - The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated 
      Hospital of Nanjing University Medical School, Nanjing, China.
FAU - Xie, Li
AU  - Xie L
AD  - The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated 
      Hospital of Nanjing University Medical School, Nanjing, China.
FAU - Shao, Jie
AU  - Shao J
AD  - The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated 
      Hospital of Nanjing University Medical School, Nanjing, China.
FAU - Yu, Lixia
AU  - Yu L
AD  - The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated 
      Hospital of Nanjing University Medical School, Nanjing, China.
FAU - Cen, Lanqi
AU  - Cen L
AD  - The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated 
      Hospital of Nanjing University Medical School, Nanjing, China.
FAU - Li, Lin
AU  - Li L
AD  - Department of Pathology of Nanjing Drum Tower Hospital, The Affiliated Hospital 
      of Nanjing University Medical School, Nanjing, China.
FAU - Liu, Fangcen
AU  - Liu F
AD  - Department of Pathology of Nanjing Drum Tower Hospital, The Affiliated Hospital 
      of Nanjing University Medical School, Nanjing, China.
FAU - Qian, Hanqing
AU  - Qian H
AD  - The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated 
      Hospital of Nanjing University Medical School, Nanjing, China.
FAU - Wei, Jia
AU  - Wei J
AD  - The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated 
      Hospital of Nanjing University Medical School, Nanjing, China.
FAU - Liu, Baorui
AU  - Liu B
AD  - The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated 
      Hospital of Nanjing University Medical School, Nanjing, China.
LA  - eng
PT  - Case Reports
DEP - 20220208
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8861377
OTO - NOTNLM
OT  - combination therapy
OT  - nano-vaccine
OT  - neoantigen
OT  - personalized
OT  - phyllodes tumor
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/02/26 06:00
MHDA- 2022/02/26 06:01
PMCR- 2022/01/01
CRDT- 2022/02/25 05:38
PHST- 2021/10/23 00:00 [received]
PHST- 2022/01/10 00:00 [accepted]
PHST- 2022/02/25 05:38 [entrez]
PHST- 2022/02/26 06:00 [pubmed]
PHST- 2022/02/26 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.800484 [doi]
PST - epublish
SO  - Front Oncol. 2022 Feb 8;12:800484. doi: 10.3389/fonc.2022.800484. eCollection 
      2022.